Monoclonal Antibody Therapy

Anti-COVID-19 Monoclonal Antibodies Information

  • Monoclonal antibody therapy has been shown to reduce the risk of developing COVID-19 after an exposure, and to reduce the risk of hospitalization or death in high-risk individuals who are infected.
  • Can be given either as an injection or infusion
  • Not FDA approved, but rather has an Emergency Use Authorization for adults and children between ages 12-17 weighing over 40 kg (88 lb)

Who qualifies for Anti-COVID-19 Monoclonal Antibodies?

The FDA defines who qualifies for Anti-COVID-19 Monoclonal Antibodies, and guidance is specific whether infected or exposed.

If infected with COVID-19

  • Individuals must have symptoms of COVID-19, be within 10 days of symptom onset and have a high-risk condition*. Persons hospitalized for COVID-19 or on supplemental oxygen are not candidates for monoclonal antibody therapy.

If exposed to COVID-19

  • Individuals must be within 7 days of exposure, have insufficient immunity to COVID (i.e. are unimmunized, incompletely immunized, or fully vaccinated but immunocompromised) and have a high-risk condition*.

*High-risk conditions:

  • Older than 65 years
  • Obesity or overweight
  • Pregnancy
  • Chronic kidney disease
  • Diabetes
  • Immunosuppressive disease or immunosuppressive treatment
  • Cardiovascular disease or high blood pressure
  • Chronic lung disease
  • Sickle cell disease
  • Neurodevelopmental disorders
  • Tracheostomy, gastrostomy, or positive pressure ventilation (not for COVID)

What to Expect

  • Call your Virginia Mason health care provider to discuss next steps if you believe you qualify for anti-COVID-19 monoclonal antibody treatment.
  • Your care team will guide you through steps to determine your eligibility, provide pre-treatment counseling, and arrange for treatment.
  • You will receive the medication either as an intravenous infusion or as 4 injections.
  • The FDA requires that you be observed for 1 hour after you have received the medication.
  • For additional information, please review the FDA patient fact sheet.